Business Wire

Janssen to Present 14 Abstracts in Prostate and Urothelial Cancers at ASCO GU 2018, Including New Data on apalutamide (ARN-509), ZYTIGA® (abiraterone acetate) and erdafitinib

Jaa

New data from the Janssen Pharmaceutical Companies of Johnson & Johnson will be presented at this year’s American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium 2018 taking place February 8-10 in San Francisco. In total, 14 company-sponsored abstracts with data for both investigational and approved compounds have been accepted for presentation, including for apalutamide and ZYTIGA® (abiraterone acetate) in prostate cancer, and for erdafitinib in urothelial cancer. Most notably, Phase 3 data results from the SPARTAN clinical trial, assessing apalutamide in non-metastatic castration-resistant prostate cancer, will be featured as part of the Prostate Cancer Oral Abstract Session on Thursday, February 8.

The data, which is being presented at ASCO GU and features a number of approved and investigational compounds, reinforces our commitment to helping transform patient outcomes. We understand that every patient with cancer will face his or her own unique journey and we are committed to helping redefine that journey,” said Dr. Ivo Winiger-Candolfi, Oncology Solid Tumor Therapy Area Lead, Janssen Pharmaceutical Companies of Johnson & Johnson. “We particularly look forward to presenting results from the pivotal SPARTAN clinical trial.”

Key company-sponsored data presentations include:

Apalutamide:

  • SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) vs placebo (PBO) in patients (pts) with non-metastatic castration-resistant prostate cancer (nmCRPC) (Abstract #161)
    • These data will be featured in an Oral Abstract Presentation during Session A of the Prostate Cancer Program from 1:00 pm – 2:30 pm PST on Thursday, February 8th

ZYTIGA ® :

  • Abiraterone acetate plus prednisone (P) 5 mg QD in metastatic castration-naïve prostate cancer (nCNPC): detailed safety analyses from the LATITUDE phase 3 trial (Abstract #182)
    • These data will be presented in a Poster Presentation Session A from 11:30am-1:00pm and 5:15 pm – 6:15 pm PST on Thursday, February 8th
  • Medical resource utilization (MRU) of abiraterone acetate plus prednisone (AAP) added to androgen deprivation therapy (ADT) in metastatic castration-naïve prostate cancer: results from LATITUDE (Abstract #201)
    • These data will be presented in a Poster Presentation Session A from 11:30am-1:00pm and 5:15 pm – 6:15 pm PST on Thursday, February 8th
  • Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naïve prostate cancer (mHNPC); Subgroup analysis of LATITUDE trial (Abstract #286)
    • These data will be featured at a Poster Session B from 12:15 pm – 1:45 pm and 6:00 pm – 7:00 pm PST on Friday, February 9th

Erdafitinib:

  • Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): phase 2 continuous versus intermittent dosing (Abstract #411)

    • These data will be featured at the Rapid Fire Abstract Session during the Urothelial Carcinoma Program from 6:00 pm –7:00 pm PST on Friday, February 9th

A full list of company-sponsored abstracts to be presented at the meeting follows below:

Abstract No.

 

Title

 

Date/Time

Apalutamide
Abstract #161   SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) vs placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC)   Oral Abstract Session A

Thursday, February 8th

1:00 pm – 2:30 pm PST

Abstract #27   Association of prostate-specific antigen (PSA) trajectories with risk for metastasis and mortality in non-metastatic castration-resistant prostate cancer (nmCRPC)   Poster Session A

Thursday, February 8th

11:30 am – 1:00 pm and 5:15 pm – 6:15 pm PST

ZYTIGA ®
Abstract #182   Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naïve prostate cancer (mCNPC): detailed safety analyses from the LATITUDE phase 3 trial   Poster Session A

Thursday, February 8th

11:30 am – 1:00 pm and 5:15 pm – 6:15 pm PST

Abstract #201   Medical resource utilization (MRU) of abiraterone acetate plus prednisone (AAP) added to androgen deprivation therapy (ADT) in metastatic castration-naïve prostate cancer: results from LATITUDE   Poster Session A

Thursday, February 8th

11:30 am –1:00 pm and 5:15 pm – 6:15pm PST

Abstract #286   Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (p) in Japanese patients with newly diagnosed, metastatic, hormone-naïve prostate cancer (mHNPC); Subgroup analysis of LATITUDE Trial   Poster Session B

Friday, February 9th

12:15 pm – 1:45 pm and 6:00 pm – 7:15 pm PST

Abstract #196   Real-world evidence in patient-related outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate plus prednisone (AA+P)   Poster Session A

Thursday, February 8th

11:30am –1:00pm and 5:15pm – 6:15pm PST

Abstract #200   Indirect treatment comparison (ITC) of abiraterone acetate (AA) plus prednisone (P) and docetaxel (DOC) on patient-reported outcomes (PROs) in metastatic castration-naïve prostate cancer (mCNPC)   Poster Session A

Thursday, February 8th

11:30 am – 1:00 pm and 5:15 pm – 6:15 pm PST

Abstract #217   Neuropsychiatric adverse events of abiraterone acetate and enzalutamide: meta-analysis of randomized clinical trials with real world reporting patterns from EudraVigilance   Poster Session A

Thursday, February 8th

11:30 am –1:00 pm and 5:15 pm –6:15 pm PST

Abstract #296   Real-world study of enzalutamide and abiraterone acetate (with prednisone) tolerability (REAAcT) - results   Poster Session B

Friday, February 9th

12:15 pm – 1:45 pm and 6:00 pm – 7:15 pm PST

Abstract #320   Real world patterns of treatment sequencing in Canada for metastatic castrate-resistant prostate cancer   Poster Session B

Friday, February 9th

12:15 pm – 1:45 pm and 6:00 pm – 7:15 pm PST

Abstract #321   Patterns of prostate cancer management across Canadian prostate cancer treatment specialists   Poster Session B

Friday, February 9th

12:15 pm – 1:45 pm and 6:00 pm – 7:15 pm PST

Abstract #343   Evolution of neuropsychiatric adverse events of abiraterone acetate and enzalutamide treatments reported in EudraVigilance, in metastatic castration resistant prostate cancer patients   Poster Session B

Friday, February 9th

12:15 pm – 1:45 pm and 6:00 pm – 7:15 pm PST

Erdafitinib
Abstract #411  

Erdafitinib (ERDA: JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): phase 2 continuous versus intermittent dosing

  Rapid Fire Abstract Session (Oral Abstract Presentation)

Friday, February 9th

6:00 pm – 7:00 pm PST

Abstract #450   Efficacy of programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors in patients with FGFR mutations and gene fusions: Results from a data analysis of an ongoing phase 2 study of erdafitinib (JNJ-42756493) in patients (pts) with advanced urothelial cancer (UC)   Poster Session B

Friday, February 9th

12:15 pm – 1:45 pm and 6:00 pm – 7:15 pm PST

   

About abiraterone acetate

Abiraterone acetate plus prednisone / prednisolone is the only approved therapy in metastatic prostate cancer that inhibits production of androgens (which fuel prostate cancer growth) at all three sources that are important in prostate cancer - the testes, adrenals and the tumour itself.1,2,3

Indications 3

In 2011, abiraterone acetate in combination with prednisone / prednisolone was approved by the European Commission (EC) for the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

In December 2012, the EC granted an extension of the indication for abiraterone acetate permitting its use, in combination with prednisone or prednisolone, for the treatment of mCRPC, in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.3

On Friday 17th November 2017, the EC granted approval in broadening the existing marketing authorisation for abiraterone acetate plus prednisone / prednisolone for the treatment of newly-diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).3

Further Information 3

The most common adverse reactions seen with abiraterone acetate plus prednisone / prednisolone that were observed in ≥10% of patients were peripheral oedema, hypokalaemia, hypertension urinary tract infection, and alanine aminotransferase increased and/or aspartate aminotransferase increased. Other important adverse reactions include, cardiac disorders, hepatotoxicity, fractures, and allergic alveolitis. For a full list of side effects and for further information on dosage and administration, contraindications and other precautions when using abiraterone acetate plus prednisone / prednisolone please refer to the summary of product characteristics, which is available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002321/WC500112858.pdf

About Apalutamide (ARN-509) 4

Apalutamide is an investigational, next-generation oral androgen receptor inhibitor that blocks the androgen signaling pathway in prostate cancer cells, and prevents binding of androgen to the androgen receptor and translocation of the androgen receptor to the nucleus of the cancer cell.

About Erdafitinib 5

Erdafitinib is a pan-fibroblast Growth Factor Receptor (FGFR) tyrosine kinase inhibitor currently being evaluated by Janssen in Phase 2 and 3 clinical trials in patients with advanced urothelial cancer. Additional research is also being conducted to explore the use of erdafitinib in other cancer indications.

About the Janssen Pharmaceutical Companies

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com/emea. Follow us at http://www.twitter.com/janssenEMEA.

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the continued development and potential of abiraterone acetate plus prednisone / prednisolone. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Janssen-Cilag International NV, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behaviour and spending patterns or financial distress of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2017, including under “Item 1A. Risk Factors,” its most recently filed Quarterly Report on Form 10-Q, including under the caption “Cautionary Note Regarding Forward-Looking Statements,” and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson. Neither the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

Date of preparation: January 2018

Job number: PHEM/ZYT/0118/0002

# # #

1 Hoy, SM. et al. Abiraterone Acetate: A review of its use in patients with metastatic castration-resistant prostate cancer drugs. Drugs 2013; 73:2077-2091.

2 Ritch, CR. Cookson, MS. Advances in the management of castration resistant prostate cancer. BMJ. 2016 Oct 17;355:i4405. Doi: 10.1136/bmj.i4405.

3 ZYTIGA® summary of product characteristics (November 2017). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002321/WC500112858.pdf. Last accessed January 2018.

4 Clegg NJ, et al. Cancer Res., 2012;72:1494-1503

5 Soria JC, et al. Poster presented at European Society for Medical Oncology conference, 7-11 October, 2016, Copenhagen, Denmark. Poster number: 781PD ClinicalTrials.Gov: NCT02365597

Contact information

Janssen
Media Enquiries:
Natalie Buhl
Phone: +353 85-744-6696
or
Investor Relations:
Lesley Fishman
Phone: +1 732-524-3922
or
Joseph J. Wolk
Phone: +1 732-524-1142

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

WELL Building Standard Gaining Momentum in Europe18.5.2018 17:47Tiedote

As Greenbuild Europe came to a close in Berlin, the International WELL Building Institute™ (IWBI™) used the occasion to highlight how the WELL Building Standard™ (WELL™) has elevated health and well-being to the forefront of sustainability conversations across Europe. WELL continues to advance the healthy building movement as the premier standard for buildings, interior spaces and communities seeking to implement, validate and measure features that promote human health and wellness. The resonance of the program has spurred innovations across the building, design and construction industries, providing projects with customizable approaches to address geographical and cultural health concerns. To date, WELL has enrolled more than 830 projects encompassing over 155 million square feet of real estate in 32 countries worldwide. In Europe nearly 190 projects across 13 countries are engaged with WELL, representing 25% of global WELL project square footage. The strong growth of WELL over the pa

Utimaco Announces Intent to Acquire Atalla from Micro Focus18.5.2018 12:03Tiedote

Utimaco, the global #2 in Hardware Security Modules (HSMs), today announced the intent to acquire the Atalla HSM and ESKM business lines from Micro Focus, which were previously owned by Hewlett Packard Enterprise (HPE) prior to the September 2017 merger of its Software business with Micro Focus. Germany-based Utimaco, active in the HSM market for over 35 years, is a global manufacturer of general purpose HSMs. Utimaco has built its market leading position focusing on indirect sales through OEM or channel business partners and selling its SecurityServer product line into industries as diverse as automotive, government, media & entertainment, smart metering, semiconductors, telecommunications and the banking and financial services sectors. Utimaco is traditionally strong in its German home market based on its longstanding German banking association certification (DK) and has recently achieved PCI accreditation for the SecurityServer product line. With the acquisition of Atalla, one of th

Janssen to Present New Data in Urothelial, Haematologic and Prostate Cancers at ASCO 2018, including Best of ASCO Selections18.5.2018 10:00Tiedote

The Janssen Pharmaceutical Companies of Johnson & Johnson, today announced 21 company-sponsored abstracts will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on June 1-5. New data analyses in support of a portfolio of products, including the investigational treatments erdafitinib and apalutamide, as well as approved treatments Imbruvica® (ibrutinib), Darzalex® (daratumumab), and Zytiga® (abiraterone acetate) will be highlighted across urothelial, haematologic and prostate cancers. Notably, Phase 2 trial results for the investigational compound erdafitinib, which received U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation, will be presented during an oral presentation on Sunday, June 3 (Abstract #4503).1,2 For haematologic cancers, Phase 3 data from the iNNOVATE study will provide the first look at ibrutinib plus rituximab versus placebo plus rituximab in patients with newly diagnosed and relapsed/refractory Wald

Karisma Hotels & Resorts to Open Allure Palazzi Kotor Bay Hotel by Karisma in June 201818.5.2018 09:00Tiedote

Karisma Hotels & Resorts, an award-winning luxury hotel collection which owns and manages properties in Latin America, the Caribbean and Europe, is pleased to announce the opening of Allure Palazzi Kotor Bay Hotel by Karisma in June 2018. Built from the ground up in Montenegro’s idyllic Dobrota, the exclusive five-star beachfront property seamlessly blends stunning architecture and design with its mountainous landscape, offering spellbinding views of Kotor Bay. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180517006456/en/ Rendering of Allure Palazzi Kotor Bay (Photo: Business Wire) Sitting on Kotor Bay’s only private beach, the resort features 89 premium guestrooms, 10 villas with private beachfront access, and three breathtaking penthouse suites, each with a balcony or terrace. Allure Palazzi Kotor Bay’s accommodations encompass sumptuous bedding, divine amenities, and carefully selected color palettes bringing the sunny

Siemens Financial Services Selects GTC’s @GlobalTrade Platform for Management of Export Documentary Credits18.5.2018 07:00Tiedote

GlobalTrade Corporation (GTC) has announced today that Siemens Financial Services (SFS) has selected its @GlobalTrade Multi-bank Trade Finance Platform for management of its export documentary credits. The platform will be initially rolled out in Germany and thereafter expanded to Siemens entities globally. The system will electronically aggregate all incoming documentary credits in a global database, facilitate review and approval, assist in preparation of compliant documents and enable faster presentation of documents electronically to advising and issuing banks. Gerhard Heubeck, Head of Trade Finance Advisory at Siemens Financial Services, reasons the need for the new system implementation as follows: "After many years of using one of the first standard IT systems available for export documentary credits, the time has come to find a successor tool capable to meet the new requirements such as multi-client capability, processing of new SWIFT message formats, global accessibility, and

PayPal Significantly Expands Global Omnichannel Platform With Acquisition of iZettle18.5.2018 01:35Tiedote

PayPal Holdings, Inc. (NASDAQ: PYPL) announced today that it has agreed to acquire iZettle, the leading small business commerce platform in Europe and Latin America, for $2.2 billion USD. The acquisition of iZettle significantly expands PayPal’s in-store presence, strengthening PayPal’s platform to help millions of small businesses around the world grow and thrive in an omnichannel retail environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180517006443/en/ Left to right: Jacob de Geer, CEO and Co-Founder of iZettle, Dan Schulman, President and CEO of PayPal, and Bill Ready, EVP, Chief Operating Officer of PayPal. (Photo: Business Wire) “Small businesses are the engine of the global economy and we are continuing to expand our platform to help them compete and win online, in-store and via mobile,” said PayPal President and CEO Dan Schulman. “iZettle and PayPal are a strategic fit, with a shared mission, values and cult

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme